Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
Launched by FONDAZIONE ITALIANA LINFOMI - ETS · Oct 3, 2023
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how long the immune response from COVID-19 vaccines and other vaccines (like those for shingles, diphtheria, and tetanus) lasts in patients with Follicular Lymphoma who are receiving specific treatments. Researchers will collect blood samples from participants at different times during their treatment to check how well their bodies are responding to these vaccines. This will help us understand the effectiveness of vaccination in people undergoing cancer treatment.
To be eligible for this study, participants need to be part of another ongoing study (called FIL_FOLL19), have received at least three doses of a COVID-19 vaccine, and have records of their vaccinations. There are no specific exclusions, so many patients may qualify. If you join the study, you can expect to provide blood samples at planned times to help the researchers gather important information about your immune response. Your involvement will contribute to valuable insights into how vaccines work for patients undergoing treatment for Follicular Lymphoma.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Enrolment in FIL_FOLL19 study
- • 2. Previous vaccination for COVID-19 (at least 3 doses)
- • 3. Availability of informations about COVID-19 and other vaccines previously administered (vaccination records)
- • 4. Willingness to comply with blood collection timepoints required for vaccination immunity evaluation
- • 5. Signature of specific informed consent form
- Exclusion Criteria:
- • None
About Fondazione Italiana Linfomi Ets
Fondazione Italiana Linfomi - ETS is a leading research organization dedicated to advancing the understanding and treatment of lymphoid malignancies. With a focus on promoting clinical trials and innovative therapeutic approaches, the foundation collaborates with healthcare professionals, academic institutions, and pharmaceutical companies to enhance patient care and outcomes. Its mission encompasses fostering research initiatives, facilitating education, and supporting the development of new strategies to combat lymphomas, ultimately aiming to improve the quality of life for patients affected by these diseases.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Firenze, , Italy
Reggio Emilia, , Italy
Alessandria, It, Italy
Biella, It, Italy
Milano, It, Italy
Milano, It, Italy
Novara, It, Italy
Pavia, It, Italy
Piacenza, It, Italy
Torino, It, Italy
Torino, It, Italy
Varese, It, Italy
Siena, , Italy
Brescia, , Italy
Avellino, Av, Italy
Patients applied
Trial Officials
Michele Merli, MD
Principal Investigator
U.O.C Ematologia, Ospedale di Circolo, Varese
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported